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LEARNING OBJECTIVES 
•  Identify biologic treatments for asthma 
refractory to traditional treatments
•  Recognize the health care burden of severe, 
persistent asthma to patients and the U.S. 
health care system
INTRODUCTION
•  Severe, persistent asthma represents a 
significant portion of morbidity and health 
care expenditure in the United States due  
to frequent emergency department visits  
for asthma exacerbation
•  Treatment for asthma exacerbation includes 
oral steroids, which may have deleterious 
long-term effects on patients
•  Biologic agents such as Mepolizumab  
or Benralizumab may be considered  
for improved daily control of severe,  
persistent asthma
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CASE PRESENTATION 
66-year-old female with a history of severe 
persistent asthma, GERD, and hypothyroidism 
presents with persistent wheezing and dyspnea 
on exertion. 
•  Uses albuterol multiple times daily with frequent 
night time awakenings
•  Daily asthma medications include fluticasone-
salmeterol, tiotropium, montelukast, theophylline, 
fluticasone propionate, cetirizine
•  FEV1/FVC ratio of 68% pre-bronchodilator and 
71% post-bronchodilator
•  Eosinophils 14%,  
Absolute eosinophils 1.2 thou/cmm
•  Bronchial thermoplasty was denied by insurance
•  Mepolizumab or benralizumab are being 
considered after patient qualifies for Medicare
MECHANISM OF ACTION
•  Benralizumab binds IL5 receptors on  
eosinophils and recruits natural killer cells  
to destroy the eosinophils
FOLLOW UP
•  Patient has started Benralizumab 30 mg/ml 
injections every 3 months with significant 
improvement in symptoms
•  Less wheezing, less chest tightness, no nocturnal 
symptoms, improved exercise tolerance
•  No need for oral prednisone
•  Considering weaning of theophylline and 
fluticasone propionate
TAKE HOME POINTS
•  Biologic treatments such as benralizumab may 
be helpful in lowering the burden of severe, 
persistent asthma for patients and the health 
care system 
•  Insurance coverage of biologic agents may 
influence the decision making process for 
patients and physicians
